Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept outcomes in treatment-naïve fellow eyes with neovascular AMD after ranibizumab failure in the first eye
KCT0002448Phase 4Completed
- Sponsor
- Bayer
- Start
- Nov 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative macular degeneration, sponsored by Bayer. Started Nov 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on KCT0002448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002448.